NasdaqCM - Delayed Quote USD

Brainstorm Cell Therapeutics Inc. (BCLI)

0.5345 +0.0025 (+0.47%)
At close: April 26 at 4:00 PM EDT
0.5552 +0.02 (+3.87%)
After hours: April 26 at 7:58 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Chaim Lebovits President & Co-CEO 878.78k -- 1971
Dr. Stacy R. Lindborg Ph.D. Co-Chief Executive Officer 751.08k -- 1971
Dr. Irit Arbel DSc, Ph.D. Co-Founder & Independent Vice Chair of the Board -- -- 1960
Ms. Alla Patlis CPA, M.B.A. Interim CFO & Controller 130.92k -- 1987
Mr. Uri Yablonka Executive VP, Chief Business Officer, Secretary & Director 247.06k -- 1977
Dr. Daniel Offen Ph.D. Chief Scientific Advisor -- -- --
Ms. Mary Kay Turner Senior Vice President of Patient Advocacy & Government Affairs -- -- --
Dr. Ibrahim Dagher M.D. Executive VP & Chief Medical Officer -- -- 1969

Brainstorm Cell Therapeutics Inc.

1325 Avenue of Americas
28th Floor
New York, NY 10019
United States
201 488 0460 https://www.brainstorm-cell.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
29

Description

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Corporate Governance

Brainstorm Cell Therapeutics Inc.’s ISS Governance QualityScore as of April 1, 2024 is 4. The pillar scores are Audit: 9; Board: 3; Shareholder Rights: 2; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 13, 2024 - May 17, 2024
Brainstorm Cell Therapeutics Inc. Earnings Call

Related Tickers

AMLX Amylyx Pharmaceuticals, Inc.
1.7600
-1.12%
 
BLRX BioLineRx Ltd.
0.6116
+6.31%
 
KZIA Kazia Therapeutics Limited
0.3700
+1.43%
 
SNGX Soligenix, Inc.
0.4150
-2.81%
 
PHRRF PharmaTher Holdings Ltd.
0.1800
0.00%
 
PXMD PaxMedica, Inc.
0.7398
+5.06%
 
TENX Tenax Therapeutics, Inc.
3.4800
-0.85%
 
KTRA Kintara Therapeutics, Inc.
0.1488
-5.82%
 
PBLA Panbela Therapeutics, Inc.
0.4100
-6.82%
 
VINC Vincerx Pharma, Inc.
0.7300
-18.59%